M. Maddula
UNSW Sydney(AU)St Vincent's Hospital Melbourne(AU)The Kinghorn Cancer Centre(AU)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Acute Ischemic Stroke Management, Immunotherapy and Immune Responses
Most-Cited Works
- → Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer—Real World Outcomes After Two Years of Therapy (COPILOT)(2024)5 cited
- → Contemporary Patterns of Care for Low-Grade Glioma in Australia and New Zealand(2025)1 cited
- → EP11.03-07 Long-term Outcomes and Toxicity in Patients with Metastatic Non Small Cell Lung Cancer Treated with Immunotherapy Containing Regimens(2023)1 cited
- → 675P Assessing later-line treatment strategies and outcomes in EGFR oncogene-driven stage IV non-small cell lung cancer(2024)
- → Assessing Second‐Line Treatment Strategies and Outcomes in Epidermal Growth Factor Receptor ( EGFR ) Oncogene‐Driven Stage IV Non‐Small Cell Lung Cancer, Following a First‐Line EGFR ‐ TKI Therapy(2025)
- → Completion Of Pembrolizumab In Advanced Non-Small Cell Lung Cancer – Real World Outcomes After Two Years of Therapy (Copilot)(2024)
- → 545P Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)(2023)
- → TIP-16. Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS (LUMOS2) study(2025)
- → Exceptional Response to Durvalumab and Tremelimumab in Pancreatic Acinar Cell Carcinoma With Ultramutated Phenotype Associated With a DNA Polymerase-ε Mutation(2026)
- → Long‐Term Outcomes and Toxicities in Patients With Metastatic Non‐Small Cell Lung Cancer Treated With Immunotherapy Containing Regimens(2025)